An observational study in Depression, sponsored by Vastra Gotaland Region. Recruiting at 3 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by Vastra Gotaland Region · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 183 studies in Depression with a site in Sweden — 34 open to participants now, 47 under way, 1 of them phase 3. Depression · Sweden.
Among the 183 studies in Depression with a site in Sweden, this one is the 24th largest by planned enrollment of the 26 observational ones that give a count, is one of 6 that started in 2026, is one of 27 observational ones, reaches primary completion later than 34 of the 46 other live ones, and was the 177th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →34 of the 183 studies in Depression with a site in Sweden are open now. Recruiting first, the newest first:
Uppsala University · Sites in Sweden
Ages 18–55
Region Stockholm · Sites in Sweden
Linkoeping University · Sites in Sweden
Ages 18+
Region Skane · Sites in Sweden
Ages 18–75 · Healthy volunteers
Region Skane · Sites in Sweden
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
183 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 13 · Phase 3 11 · Phase 4 4
First in 1998; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 175 across 1,261 observational studies indexed under Depression.
Median enrollment 113 across the 156 interventional studies, 140 across the 26 observational. Of the 122 that completed or were terminated, 10 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 183 have an industry lead sponsor. The 10 most frequent:
Vastra Gotaland Region is the lead sponsor of 276 studies on the registry; 110 are open to participants now.
Vastra Gotaland Region has 6 studies filed under Depression — fewer than ten, so there is no comparison to draw.
9 of the studies in Depression with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06549777Monique PfaltzBody-oriented Psychotherapy for Individuals With a History of Child Maltreatment and Trauma-related Symptoms | 2026-11 |
| NCT06145555Karolinska InstitutetAcute Psychological Sleep Stabilisation for Patients Hospitalised With Depression | 2026-12 |
| NCT07078227Region SkaneLong-term Follow-up of Depressive Disorders in Psychiatric Care | 2026-12-31 |
| NCT06138678Vastra Gotaland RegionVGR Accelerated TMS Treatment for Depression | 2027-01-01 |
| NCT07706816Uppsala UniversityEvaluation of a Remote Behavioural Stress Recovery Intervention for Myocardial Infarction Patients Younger Than Fifty-five (BRIM-55): A Feasibility Study | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 183 studies in Depression with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Intermittent theta-burst stimulation (iTBS), a variant of repetitive transcranial magnetic stimulation (rTMS), is a well-documented treatment for depression. The aim of this study is to evaluate the effectiveness of an accelerated iTBS protocol (1W-AiTBS) in routine clinical practice. In the accelerated protocol, patients receive 600 pulses per session, for a total of 30 sessions administered over 5-14 treatment days. Patient inclusion will take place over a maximum period of 1.5 years, with a maximum sample size of 150 patients. The target sample size is at least 36 patients. Patients will complete self-rating questionnaires at screening, before and after treatment, and at 6 weeks, 12 weeks, and 6 months from the first day of treatment.
Patients referred for AiTBS treatment at participating study sites will be invited to participate in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Magnetic pulses of 80% of visual motor threshold applied in triplets of 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 20 s over the left DLPFC (F3), given in a maximum of 8 sessions per day (\>15 min interval), total of 30 treatments on total of 10 week days.
Device: iTBS (intermittent theta-burst stimulation)
The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil. The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head.
Difference in MADRS-S from baseline to six weeks after first iTBS treatment
The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms
Time frame: 6 weeks
Difference in MADRS-S from baseline to after last iTBS treatment
The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms
Time frame: 2 weeks
Difference in MADRS-S from baseline to twelve weeks after first iTBS treatment
The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms
Time frame: 12 weeks
Difference in MADRS-S from baseline to six months after first iTBS treatment
The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms
Time frame: 6 months
Difference in SDS from baseline to twelve weeks after first iTBS treatment
The Sheehan Disability Scale (SDS) is a self-rating assessment (0-30 points), where a higher score indicates more pronounced functional impairment
Time frame: 12 weeks
Difference in SDS from baseline to six months after first iTBS treatment
The Sheehan Disability Scale (SDS) is a self-rating assessment (0-30 points), where a higher score indicates more pronounced functional impairment
Time frame: 6 months
Difference in EQ-VAS from baseline to after last iTBS treatment
The EQ-5D visual analogue scale (EQ-VAS) is a self-rating assessment (VAS 0-100 points), where a higher (VAS) score indicates a higher health-related quality of life
Time frame: 2 weeks
Difference in EQ-VAS from baseline to six weeks after first iTBS treatment
The EQ-5D visual analogue scale (EQ-VAS) is a self-rating assessment (VAS 0-100 points), where a higher (VAS) score indicates a higher health-related quality of life
Time frame: 6 weeks
Difference in EQ-VAS from baseline to twelve weeks after first iTBS treatment
The EQ-5D visual analogue scale (EQ-VAS) is a self-rating assessment (VAS 0-100 points), where a higher (VAS) score indicates a higher health-related quality of life
Time frame: 12 weeks
Difference in EQ-VAS from baseline to six months after first iTBS treatment
The EQ-5D visual analogue scale (EQ-VAS) is a self-rating assessment (VAS 0-100 points), where a higher (VAS) score indicates a higher health-related quality of life
Time frame: 6 months
Difference in reported potential side effects from baseline to after last iTBS treatment
A patient-reported form including the most commonly reported side effects of rTMS.
Time frame: 2 weeks
Difference in reported potential side effects from baseline to six weeks after first iTBS treatment
A patient-reported form including the most commonly reported side effects of rTMS.
Time frame: 6 weeks
Difference in reported potential side effects from baseline to twelve weeks after first iTBS treatment
A patient-reported form including the most commonly reported side effects of rTMS.
Time frame: 12 weeks
Difference in reported potential side effects from baseline to six months after first iTBS treatment
A patient-reported form including the most commonly reported side effects of rTMS.
Time frame: 6 months
rTMS associated pain experience
A patient-reported form rating experience of pain (scale 1 to 10) during rTMS treatment. Performed after last treatment series
Time frame: 2 weeks
Number of patients in remission after last iTBS treatment
A patient with a MADRS-S score of \< 10 is considered to be in remission
Time frame: 2 weeks
Number of patients in remission six weeks after first iTBS treatment
A patient with a MADRS-S score of \< 10 is considered to be in remission
Time frame: 6 weeks
Number of patients in remission twelve weeks after first iTBS treatment
A patient with a MADRS-S score of \< 10 is considered to be in remission
Time frame: 12 weeks
Number of patients in remission six months after first iTBS treatment
A patient with a MADRS-S score of \< 10 is considered to be in remission
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.
Of 463 non-industry observational studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 63. This study's planned 12 months is below that.
Counting every sponsor, half of 496 studies reached it within 32 months; a quarter within 13 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.